- Home
- WVE vs NGD Comparison
WVE vs NGD Comparison
Compare WVE & NGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WVE
- NGD
- Stock Information
- Founded
- WVE 2012
- NGD N/A
- Country
- WVE Singapore
- NGD Canada
- Employees
- WVE N/A
- NGD N/A
- Industry
- WVE Biotechnology: Pharmaceutical Preparations
- NGD
- Sector
- WVE Health Care
- NGD
- Exchange
- WVE Nasdaq
- NGD Nasdaq
- Market Cap
- WVE 2.1B
- NGD 2.0B
- IPO Year
- WVE 2015
- NGD 2004
- Fundamental
- Price
- WVE $13.70
- NGD $2.64
- Analyst Decision
- WVE Strong Buy
- NGD Buy
- Analyst Count
- WVE 10
- NGD 4
- Target Price
- WVE $21.60
- NGD $3.04
- AVG Volume (30 Days)
- WVE 947.4K
- NGD 8.0M
- Earning Date
- WVE 11-12-2024
- NGD 02-11-2025
- Dividend Yield
- WVE N/A
- NGD N/A
- EPS Growth
- WVE N/A
- NGD N/A
- EPS
- WVE N/A
- NGD 0.02
- Revenue
- WVE $53,610,000.00
- NGD $861,500,000.00
- Revenue This Year
- WVE N/A
- NGD $22.53
- Revenue Next Year
- WVE $48.58
- NGD $31.05
- P/E Ratio
- WVE N/A
- NGD $112.53
- Revenue Growth
- WVE N/A
- NGD 14.85
- 52 Week Low
- WVE $3.50
- NGD $1.09
- 52 Week High
- WVE $16.74
- NGD $3.25
- Technical
- Relative Strength Index (RSI)
- WVE 48.19
- NGD 42.57
- Support Level
- WVE $13.11
- NGD $2.78
- Resistance Level
- WVE $15.54
- NGD $3.08
- Average True Range (ATR)
- WVE 0.89
- NGD 0.11
- MACD
- WVE -0.19
- NGD -0.02
- Stochastic Oscillator
- WVE 27.52
- NGD 7.45
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
About NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.